On August 9, 2024, the "Beijing Pharmaceutical Innovation and Investment Development Seminar and
On April 3, 2024, under the guidance of the Party Committee of the Shenzhen Biomedical Industry Innova
On the afternoon of February 29, 2024, R&G PharmaStudies Co., Ltd., in collaboration with Shenzhe
From March 21 to 24, 2024, the Innovative Medicine Conference and the 2024 CMAC Annual Meeting, the
On January 5, 2024, the official website of the National Medical Products Administration (NMPA) anno
On January 29, 2024, the 22nd communication meeting of the "Open Day of the Clinical Trial Institu
Figure 1: On-site Photo of the Night of Chinese Pharmaceutical Innovation and DevelopmentOn November
On October 28, 2023, with the theme "R&G's Ideals Are Higher Than the Sky", the gra
TIL therapy is considered one of the most competitive and commercially promising technological directions i
From June 29 to 30, 2023, BIO-PHARM2023 and the grand award ceremony of the Huayi List - 2023 Chi
From June 17 to 19, 2023, the 2023 DIA China Annual Meeting and Exhibition was grandly held at the S
Abstract: Dialogue with Dr. Gang Chen, Chief Scientific Officer and Dr. Kun He, Chief Statisticia
Since the reform of the drug review and approval system in 2015, the domestic innovative drug industry has be
On December 30, 2022, the Second China Biopharmaceutical Industry Chain Innovation and Transformation
On August 02, 2022, the launch ceremony of the initial public offering of A-shares by R&G PharmaStu
